Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians
(Thomson Reuters ONE) -
Novartis International AG /
Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS
assessment methods to benefit patients and physicians
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* New analysis will confirm high efficacy of Gilenya® in achieving 'no
evidence of disease activity' (NEDA4) in previously-treated highly-active
RMS patients
* Separate analyses will show adding brain shrinkage to an existing assessment
tool enhances ability to predict disability progression in relapsing MS
(RMS)
* Early data on a novel method to assess motor function in patients with MS
and its potential clinical application will also be presented at AAN
Basel, 13 April 2015 - Novartis announced today new Gilenya® analyses to be
presented at the 67th American Academy of Neurology (AAN) Annual Meeting in
Washington, DC, USA from April 18-25, 2015, showing how Novartis is advancing
methods assessing the impact of relapsing multiple sclerosis (RMS) for patients
and physicians. Data will show how adding brain shrinkage (brain volume loss) to
an existing tool to assess MS disease activity (m-Rio) will give a more precise
prediction of the likelihood of future disability progression. Accurate
assessment of disease activity is key to guide treatment decisions in RMS.
A pooled analysis from the two-year phase III FREEDOMS and FREEDOMS II trials
will further confirm Gilenya's high efficacy in previously-treated patients with
highly-active RMS in achieving 'no evidence of disease activity' (NEDA4) across
four key measures: relapses, MRI lesions, brain shrinkage and disability
progression[1],[2]. Achieving NEDA4 is especially critical for highly-active RMS
patients, who are likely to lose more physical and cognitive functions over time
despite being treated.
"Novartis is committed to innovation beyond the research and development of new
treatments, to help physicians and patients improve how multiple sclerosis is
managed," said Vasant Narasimhan, Global Head of Development at Novartis
Pharmaceuticals. "These Gilenya data and new methods of assessing the impact of
MS have the potential to give physicians a more comprehensive picture of an
individual's disease and allow patients to better understand their MS."
Additional data will also be presented on ASSESS-MS, a project in early
development which uses an innovative movement recording system and aims to
quantify an individual's level of disability in a non-invasive, patient-friendly
manner. It measures a patient's movements using the Microsoft Kinect(®*) sensor
with machine learning algorithms. Developed in collaboration with leading MS
experts and Microsoft Research, ASSESS-MS may have the potential to change how
neurological dysfunction and disability progression are assessed in MS
patients[3],[4],[5].
Novartis MS portfolio highlights at AAN will include three poster presentations
on ASSESS-MS; 16 presentations on Gilenya trial analyses; and one poster
presentation on BAF312, an S1P-modulator that is being investigated for
secondary progressive MS (SPMS).
About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disorder of the central nervous system
(CNS) that disrupts the normal functioning of the brain, optic nerves and spinal
cord through inflammation and tissue loss[6] The evolution of MS results in an
increasing loss of both physical and cognitive (e.g. memory) function[7]. This
has a substantial negative impact on the approximately 2.3 million people
worldwide affected by MS[8], a disease that most often begins in early
adulthood[9].
People with MS can be diagnosed with relapsing forms of MS (RMS), which include
relapsing remitting MS (RRMS) and secondary progressive MS (SPMS)[10], or with
primary progressive MS (PPMS).
The loss of physical and cognitive function in RMS is driven by two types of
damage that result in the loss of neurons and brain tissue - distinct
inflammatory lesions (referred to as focal damage), and more widespread
inflammatory neurodegenerative processes (referred to as diffuse damage). Focal
damage results in the loss of brain tissue and can clinically present as
relapses. Diffuse damage starts early in the disease, often goes unnoticed and
is also associated with loss of brain tissue and accumulated loss of
function[11-13].
About Gilenya
Gilenya is the only oral disease-modifying therapy (DMT) to impact the course of
relapsing MS (RMS) with high efficacy across four key measures of disease
activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and
disability progression[14-18]. Gilenya is approved in the US for the first-line
treatment of relapsing forms of MS in adults[19]. In the EU, Gilenya is
indicated for adult patients with highly active relapsing-remitting MS (RRMS)
defined as either high disease activity despite treatment with at least one DMT,
or rapidly evolving severe RRMS[20].
Gilenya targets both focal and diffuse CNS damage. It prevents cells that cause
focal inflammation from reaching the brain (referred to as 'peripheral' action),
but also enters the CNS and reduces the diffuse damage by preventing the
activation of harmful cells residing in the CNS (referred to as 'central
action')[21-23]. It is important to address both focal and diffuse damage in
relapsing MS to effectively impact disease activity and help preserve an
individual's functions[7].
The safety profile of Gilenya in RMS is well understood and based on substantial
evidence from three major clinical trials and extensive real-world experience in
more than 114,000 patients, with the total patient exposure now at approximately
195,000 patient years[23].
About Novartis in Multiple Sclerosis
Novartis is committed to the research and development of new treatment options
to offer the right treatment to the right patient at the right time, to meet
patients' needs at every stage of disease with innovative and targeted drugs.
In addition to its ongoing development program for Gilenya in pediatric MS and
chronic inflammatory demyelinating polyneuropathy (CIDP), the Novartis MS
portfolio includes Extavia(®) (interferon beta-1b for subcutaneous injection).
Investigational compounds include BAF312, currently in phase III clinical
development and being investigated as an oral therapy for secondary progressive
MS (SPMS). Novartis is also exploring the IL-17 pathway in MS.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "to highlight," "will," "to be presented," "committed,"
"potential," "being investigated," "ongoing," "investigational," "exploring," or
similar terms, or by express or implied discussions regarding potential future
indications or labeling for Gilenya, potential future marketing submissions or
approvals for the other investigational compounds in the Novartis MS portfolio,
or regarding potential future revenues from any or all of the products and
investigational compounds in the Novartis MS portfolio, including Gilenya. You
should not place undue reliance on these statements. Such forward-looking
statements are based on the current beliefs and expectations of management
regarding future events, and are subject to significant known and unknown risks
and uncertainties. Should one or more of these risks or uncertainties
materialize, or should underlying assumptions prove incorrect, actual results
may vary materially from those set forth in the forward-looking statements.
There can be no guarantee that Gilenya will be submitted or approved for any
additional indications or labeling in any market, or at any particular time. Nor
can there be any guarantee that any of the investigational compounds in the
Novartis MS portfolio will be submitted or approved for sale in any market, or
at any particular time. Neither can there be any guarantee that any of the
products and investigational compounds in the Novartis MS portfolio will be
commercially successful in the future. In particular, management's expectations
regarding these products could be affected by, among other things, the
uncertainties inherent in research and development, including unexpected
clinical trial results and additional analysis of existing clinical data;
unexpected regulatory actions or delays or government regulation generally; the
company's ability to obtain or maintain proprietary intellectual property
protection; general economic and industry conditions; global trends toward
health care cost containment, including ongoing pricing pressures; unexpected
manufacturing issues, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care, cost-saving generic pharmaceuticals, preventive vaccines and over-the-
counter products. Novartis is the only global company with leading positions in
these areas. In 2014, the Group achieved net sales of USD 58 billion, while R&D
throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion
excluding impairment and amortization charges). Novartis Group companies employ
approximately 130,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visit http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
* Kinect(®) is a registered trademark of Microsoft Corporation.
References
[1] De Stefano N et al. Impact of fingolimod on achieving no evidence of disease
activity and worsening (NEDA)-4 in previously treated patients with high disease
activity. Poster to be presented at: 67th AAN Annual Meeting; April 18 -
25, 2015; Washington, DC. Poster Session III, P3.246.
[2] Montalban X et al. Effect of fingolimod versus interferon-beta1a on no
evidence of disease activity or worsening (NEDA-4) in the TRANSFORMS study.
Poster to be presented at: 67th AAN Annual Meeting; April 18 - 25, 2015;
Washington, DC. Poster Session IV, P4.001.
[3] Morrison C et al. Usability and acceptability of the ASSESS MS movement
recording tool in Multiple Sclerosis using depth-sensing computer vision.
Abstract to be presented at: 67th AAN Annual Meeting; April 18 - 25, 2015;
Washington, DC. Poster Session III, P3.220.
[4] Dorn J et al. Automation of clinical assessments via machine learning and
paired comparison. Abstract to be presented at: 67th AAN Annual Meeting; April
18 - 25, 2015; Washington, DC. Poster Session IV, P4.205.
[5] D`Souza M, Automated quantification of motor dysfunction in multiple
sclerosis using depth-sensing computer vision. Abstract to be presented at:
67th AAN Annual Meeting; April 18 - 25, 2015; Washington, DC. Poster Session
III, P3.213.
[6] http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/. Accessed March 2015.
[7] http://www.nationalmssociety.org/Symptoms-Diagnosis/MS-Symptoms. Accessed
March 2015.
[8] http://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf. Accessed
March 2015.
[9] http://emsp.org/multiple-sclerosis/ms-fact-sheet. Accessed March 2015.
[10]
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/0
3/WC500185161.pdf. Accessed March 2015.
[11] Filippi M et al. Association between pathological and MRI findings in
multiple sclerosis. Lancet Neurol. 2012 Apr;11(4):349-60.
[12] Kutzelnigg A et al. Cortical demyelination and diffuse white matter injury
in multiple sclerosis. Brain. 2005 Nov;128(Pt 11):2705-12.
[13] Sormani MP, Arnold DL & De Stefano N. Treatment effect on brain atrophy
correlates with treatment effect on disability in multiple sclerosis. Ann
Neurol. 2014 Jan;75(1):43-9.
[14] Cohen JA et al.; for TRANSFORMS Study Group. Oral fingolimod or
intramuscular interferon for relapsing multiple sclerosis. N Engl J Med.
2010;362(5):402-415.
[15] Kappos L et al.; for FREEDOMS Study Group. A placebo-controlled trial of
oral fingolimod in relapsing multiple sclerosis.
[16] Montalban et al. Long-term efficacy of fingolimod in patients with
relapsing-remitting multiple sclerosis previously treated with interferon beta-
1a or disease-modifying therapies: A Post-hoc analysis of the TRANSFORMS 4.5
year extension study. European Neurological Society, June 10, 2013 P539.
[17] Kappos L et al. Phase 3 FREEDOMS study extension: fingolimod (FTY720)
efficacy in patients with relapsing-remitting multiple sclerosis receiving
continuous or placebo-fingolimod switched therapy for up to 4 years. Poster
presented at: 28th Congress of the European Committee for Treatment and Research
in Multiple Sclerosis; October 10-13, 2012; Lyon, France. Poster P979.
[18] Chin PS et al. Early effect of fingolimod on clinical and MRI related
outcomes in relapsing multiple sclerosis. Poster presented at: 28th Congress of
the European Committee for Treatment and Research in Multiple Sclerosis; October
10-13, 2012; Lyon, France. Abstract P459.
[19] http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022527s008mg.pdf.
Accessed March 2015.
[20] http://ec.europa.eu/health/documents/community-register/html/h677.htm.
Accessed March 2015.
[21] Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects
in the immune and the central nervous system. Br J Pharmacol
2009;158(5):1173-1182.
[22] Chun J & Hartung HP. Mechanism of Action of Oral Fingolimod (FTY720) in
Multiple Sclerosis. Clin Neuropharmacol. 2010 March-April;33(2):91-101.
[23] Data on file. Novartis Pharmaceuticals.
# # #
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Angela Fiorin
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41 61 324 8631 (direct)
+41 79 593 4202 (mobile) +41 79 752 6955 (mobile)
eric.althoff(at)novartis.com angela.fiorin(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: |+41 61 324 7944 | |
----------------------+-----------------+--------------+----------------------
Samir Shah |+41 61 324 7944 |North America:|
----------------------+-----------------+--------------+----------------------
Pierre-Michel Bringer|+41 61 324 1065 |Richard Pulik |+1 212 830 2448
----------------------+-----------------+--------------+----------------------
Thomas Hungerbuehler |+41 61 324 8425 |Susan Donofrio|+1 862 778 9257
----------------------+-----------------+--------------+----------------------
Isabella Zinck |+41 61 324 7188 | |
----------------------+-----------------+--------------+----------------------
| | |
----------------------+-----------------+--------------+----------------------
e-mail: investor.relations(at)novartis.com|e-mail:
|investor.relations(at)novartis.com
----------------------------------------+-------------------------------------
|
Media release (PDF):
http://hugin.info/134323/R/1910391/681247.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1910391]
Unternehmensinformation / Kurzprofil:
Datum: 13.04.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 384988
Anzahl Zeichen: 18344
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 174 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
